Table 1.

Correlation of clinicopathological data of breast cancer patients with TGIF expression levels

Parameter	Category	Overall		TGIF expression				p-value
				0–2		3–12
		N	%	N	%	N	%
All patients		1197		475	39.7%	722	60.3%
Age (years)	< 40	185	15.5%	73	15.4%	112	15.5%	0.756
	40–50	489	40.9	196	41.3%	293	40.6%
	51–65	496	41.4%	56	48.7%	440	40.7%
	> 65	27	2.3%	8	1.7%	19	2.6%
Tumor stage (pT)	pT1	394	33.0%	134	28.4%	260	36.1%	0.015
	pT2	665	55.7%	286	60.6%	379	52.6%
	pT3/4	134	11.2%	52	11.0%	82	11.4%
	total	1193		472		721
	missing	4
Lymph node status (pN)	pN1	493	41.2%	181	38.1%	312	43.2%	0.114
	pN2	398	33.2%	159	33.5%	239	33.1%
	pN3	306	25.6%	135	28.4%	171	23.7%
Tumor grading (G)	G1	39	3.3%	13	2.7%	26	3.6%	< 0.001
	G2	588	49.2%	196	41.4%	392	54.3%
	G3	569	47.6%	265	55.9%	304	42.1%
	missing	1
Histological type	ductal	930	77.7%	389	81.9%	541	74.9%	0.009
	lobular	136	11.4%	39	8.2%	97	13.4%
	others	131	10.9%	47	9.9%	84	11.6%
HER2	positive	248	22.0%	89	20.4%	159	23.0%	0.303
	negative	880	78.0%	348	79.6%	532	77.0%
	missing	69
ER	positive	886	74.0%	322	67.8%	564	78.1%	< 0.001
	negative	311	26.0%	153	32.2%	158	21.9%
PR	positive	819	68.4%	285	60.0%	534	74.0%	< 0.001
	negative	378	31.6%	190	40.0%	188	26.0%
Treatment in mITTset	iddEPC	597	49.9%	232	48.8%	365	50.6%	0.595
	ddEC-PwX	600	50.1%	243	51.2%	357	49.4%
Ibandronate treatment	with Ibandronate	781	65.2%	307	64.6%	474	65.7%	0.756
	without Ibandronate	416	34.8%	168	35.4%	248	34.3%

Data are N (valid %) unless otherwise state

mITT modified intention-to treat, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor, iddEPC intense dose-dense epirubicin plus paclitaxel plus cyclophosphamide, ddEC-PwX dose-dense epirubicin plus cyclophosphamide plus paclitaxel weekly and capecitabine